{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CCRT%28concurrent+chemoradiation+therapy%29", "query": { "intervention": "CCRT(concurrent chemoradiation therapy)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CCRT%28concurrent+chemoradiation+therapy%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T02:58:17.340Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04952597", "title": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Limited Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Concurrent Chemoradiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2021-07-15", "completion_date": "2023-07-26", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952597" }, { "nct_id": "NCT06667908", "title": "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "JNJ-90301900", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT)", "type": "RADIATION" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin", "type": "DRUG" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Johnson & Johnson Enterprise Innovation Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2024-12-06", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 18, "location_summary": "La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06667908" }, { "nct_id": "NCT03745222", "title": "A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Concurrent chemoradiotherapy (cCRT)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-05-22", "completion_date": "2019-06-26", "has_results": true, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 14, "location_summary": "Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745222" }, { "nct_id": "NCT05353257", "title": "A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Limited-Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "HLX10", "type": "DRUG" }, { "name": "carboplatin/cisplatin-etoposide", "type": "DRUG" }, { "name": "Thoracic radiotherapy", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prophylactic Cranial Irradiation (PCI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 511, "start_date": "2022-05-17", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 31, "location_summary": "Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05353257" }, { "nct_id": "NCT04680377", "title": "Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NSCLC, Stage III", "Locally Advanced Lung Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2021-04-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 2, "location_summary": "Kansas City, Kansas • Providence, Rhode Island", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04680377" }, { "nct_id": "NCT07566156", "title": "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer", "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Conventional Radiotherapy", "type": "RADIATION" }, { "name": "Hypofractionated Radiotherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2026-05-11", "completion_date": "2032-02-29", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 13, "location_summary": "Santa Barbara, California • Aurora, Colorado • Newark, Delaware + 10 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Niles", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07566156" }, { "nct_id": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "RP3", "type": "BIOLOGICAL" }, { "name": "CCRT(concurrent chemoradiation therapy)", "type": "OTHER" }, { "name": "carboplatin and paclitaxel", "type": "OTHER" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-30", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743270" }, { "nct_id": "NCT03830866", "title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Cervical Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "external beam radiation therapy (EBRT) + brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 770, "start_date": "2019-02-15", "completion_date": "2023-07-03", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 16, "location_summary": "Phoenix, Arizona • La Jolla, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03830866" }, { "nct_id": "NCT02485470", "title": "Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "MPACT", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 5, "start_date": "2016-02", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02485470" }, { "nct_id": "NCT03840902", "title": "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2019-04-16", "completion_date": "2023-02-17", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-09-25T02:58:17.340Z", "location_count": 21, "location_summary": "Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840902" } ] }